We invite you to join us to discuss selected acute leukemia abstracts from EHA 2026

We invite you to join a discussion about the upcoming CLSG-ALL-2 Trial.

We invite you to join a discussion about the management of FLT3-mutated AML and what’s new in 2026. The discussion will cover the impact of newly available Quizartinib on Canadian practice, and recent advances in FLT3-ITD MRD testing.